TMX-201 (C007B-430813)

TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma researchIn VitroTMX-201 is more potent cytokine inducer than Imiquimod (HY-B0180) in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoThe maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg . TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects . TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:TLR7. Specification: ≥98.0% Molecular Formula: C57H93N6O12P Molecular Weight: 1085.36

UPC:

41181942

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

WeightUOM:

LB

MPN:

T649137-25mg

CAS:

1149339-78-5

Product Size:

25mg